Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

키워드

참고문헌 (10)

1. Tsai YN, "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation", Clin Mol Hepatol, 30, pp.98~108 (2024)
2. Huang PY, "The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients", J Viral Hepat, 28, pp.1141~1149 (2021)
3. Chen CH, "Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy", Hepatol Int, 14, pp.317~325 (2020)
4. Jeng WJ, "Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis", Hepatology, 79, pp.690~703 (2024)
5. Berg T, "The times they are a-changing-A refined proposal for finite HBV nucleos(t)ide analogue therapy", J Hepatol, 75, pp.474~480 (2021)
6. Liaw YF, "Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B : From an"option"to an"active recommendation"", Kaohsiung J Med Sci, 38, pp.295~301 (2022)
7. Hall SAL, "Stopping nucleot(s)ide analogues in noncirrhotic HBeAg-negative chronic hepatitis B patients : HBsAg loss at 96 weeks is associated with low baseline HBsAg levels", Aliment Pharmacol Ther, 56, pp.310~320 (2022)
8. Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
9. Mak LY, "Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B", Clin Mol Hepatol, 29, pp.146~162 (2023)
10. Liaw YF, "Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection", Nat Rev Gastroenterol Hepatol, 16, pp.631~641 (2019)

관련 논문AI추천